Analytical Data
-
Gene name
HLA-A*02:01&B2M&HPV(TIHDIILECV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & HPV (TIHDIILECV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&TIHDIILECV
-
Molecular Weight
40-43 kDa and 12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/HPV(TIHDIILECV) monomer recombinant protein is situated within the essential context of immunology and cancer research. Human leukocyte antigen (HLA) molecules, particularly HLA-A*02:01, play a pivotal role in the immune system by presenting peptide fragments derived from proteins, including those from human papillomavirus (HPV), to CD8+ T cells. HPV is a well-known etiological agent in cervical cancer and other malignancies, making the understanding of its interaction with HLA molecules critical for vaccine development and immunotherapeutic strategies. The specific peptide TIHDIILECV derived from the HPV-E7 protein has been shown to elicit a robust immune response, particularly in individuals with HLA-A*02:01, which is one of the most common HLA alleles. By developing a monomeric recombinant protein complex of HLA-A*02:01, beta-2-microglobulin (B2M), and the HPV peptide, researchers aim to investigate its structural characteristics and stability, as well as its interactions with T cell receptors. This research may illuminate mechanisms of immune recognition and contribute to the design of targeted immunotherapies that enhance the efficacy of the anti-HPV immune response, potentially leading to improved treatment options for HPV-associated cancers.
